NET-6 Inhibitors
Chemical inhibitors of NET-6 function through various signaling pathways integral to the protein's role in cellular processes. Wortmannin and LY294002 act as potent inhibitors of phosphoinositide 3-kinases (PI3K), which are upstream of AKT signaling, a pathway requisite for NET-6 functionality. The inhibition of PI3K by these chemicals results in the suppression of AKT phosphorylation and subsequent activity, leading to a decrease in NET-6 function. Rapamycin targets the mTOR pathway, which operates downstream of PI3K/AKT and is essential for NET-6-related cellular activities. By inhibiting mTOR, Rapamycin disrupts the signaling necessary for NET-6's role in the cell. Similarly, PD98059 and U0126 inhibit the MEK1/2, which are upstream of the ERK/MAPK pathway, a critical regulator of NET-6 function. The prevention of MEK activation by these chemicals leads to reduced ERK/MAPK pathway signaling and a consequent functional decrease in NET-6 activity.
The JNK inhibitor SP600125 and the p38 MAP kinase inhibitor SB203580 disrupt the JNK and p38 MAP kinase pathways, respectively, both of which can regulate NET-6 function. The inhibition of these kinases by SP600125 and SB203580 results in diminished signaling processes necessary for NET-6. Additionally, PP2 and Dasatinib, which inhibit Src family tyrosine kinases, impair the Src kinase-mediated regulatory mechanisms on which NET-6 activity depends. PF-4708671 specifically targets p70 ribosomal S6 kinase 1 (S6K1), a component of the signaling network involving PI3K/AKT and mTOR pathways that influence NET-6 function. The inhibition of S6K1 by PF-4708671 thereby disrupts the signaling required for NET-6 activity. LY3214996 directly inhibits ERK1/2 within the MAPK pathway, leading to a decrease in NET-6 activity due to reduced ERK1/2 signaling. Lastly, SL 0101-1's inhibition of ribosomal S6 kinase (RSK), regulated by the ERK/MAPK pathway, culminates in a functional downregulation of NET-6 due to the RSK's role in NET-6's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in a variety of cellular processes including those regulated by NET-6. Inhibition of PI3K can lead to reduced AKT phosphorylation and activity, a pathway necessary for the function of NET-6. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another well-known inhibitor of PI3K, leading to diminished AKT signaling. Since AKT pathway activity is crucial for the function of NET-6, disruption of this pathway by LY294002 leads to functional inhibition of NET-6. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), which is downstream of PI3K/AKT signaling. Given that mTOR activity is essential for several cellular processes involving NET-6, its inhibition by Rapamycin can suppress NET-6 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the ERK/MAPK pathway. NET-6, involved in cellular signaling, can be functionally inhibited by disrupting this pathway, as MEK is upstream of cellular processes regulated by NET-6. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of a signaling cascade that can influence NET-6 activity. By inhibiting JNK, SP600125 effectively disrupts signaling processes that are essential for NET-6 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, another signaling molecule that can be upstream of NET-6 function. Inhibition of p38 MAP kinase leads to decreased activity of pathways necessary for the function of NET-6. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Src kinases are involved in a variety of signaling pathways that can regulate NET-6 activity. By inhibiting Src kinases, PP2 can lead to a decrease in NET-6 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, preventing the activation of the ERK/MAPK pathway. As this pathway is critical for NET-6 activity, its inhibition by U0126 would result in decreased NET-6 function. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $260.00 | ||
LY3214996 specifically inhibits ERK1/2, which are integral components of the MAPK pathway. Because ERK1/2 signaling is necessary for NET-6 function, inhibition by LY3214996 decreases NET-6 activity. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $175.00 $700.00 | 9 | |
PF-4708671 is a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1). S6K1 is downstream of PI3K/AKT and mTOR pathways, which are involved in NET-6 function. By inhibiting S6K1, PF-4708671 disrupts the signaling required for NET-6 function. | ||||||